Get the Stockscreener App
22.47
1.23%
-0.28
Pre-market:
23.68
1.21
+5.38%
Enliven Therapeutics Inc Stock (ELVN) Forecast
The Enliven Therapeutics Inc (ELVN) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $8.9615, representing a -60.12% decrease from the current price of $22.47. The highest analyst price target is $11.77, and the lowest is $6.1509.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ELVN Price Target
Average 14.36
(-36.10% Downside)
Is Enliven Therapeutics Inc (ELVN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 51.07 | Neutral |
| STOCH(9,6) | 66.37 | Neutral |
| STOCHRSI(14) | 84.60 | Sell |
| MACD(12,26) | -0.2923 | Buy |
| ADX(14) | 17.67 | Neutral |
| William %R | -25.54 | Neutral |
| CCI(14) | 89.55 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
21.73
Buy
|
22.02
Buy
|
| MA20 |
21.90
Buy
|
22.13
Buy
|
| MA50 |
22.98
Sell
|
23.01
Sell
|
| MA100 |
24.73
Sell
|
23.52
Sell
|
| MA200 |
23.57
Sell
|
22.25
Buy
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, ELVN could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 6 signaling Sell signals and 5 Neutral signals. This suggests that investors should exercise caution when entering new positions on ELVN, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 51.07 indicates that ELVN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 66.37 indicates that ELVN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 84.6 indicates that ELVN is oversold. This suggests that ELVN price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.67 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 89.55 indicates that ELVN is still overbought but not to an extreme extent.
Long-term ELVN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Enliven Therapeutics Inc financial reports and earnings history, Enliven Therapeutics Inc (ELVN) stock could reach $2.6933 by 2030, $31.33 by 2040 and $58.08 by 2050. See the projected annual prices until 2050 of the Enliven Therapeutics Inc stock below:
- Enliven Therapeutics Inc (ELVN) is expected to reach an average price of $15.30 in 2035, with a high prediction of $14.94 and a low estimate of $14.53. This indicates an $-31.91% rise from the last recorded price of $22.47.
- Enliven Therapeutics Inc (ELVN) stock is projected to chart a bullish course in 2040, with an average price target of $35.33, representing an $57.22% surge from its current level. The forecast ranges from a conservative $32.06 to a sky-high $31.33.
- Our analysts predict Enliven Therapeutics Inc (ELVN) to jump 67.78% by 2045, soaring from $38.48 to an average price of $37.70, potentially reaching $40.96. While $38.48 is the low estimate, the potential upside is significant.
- Enliven Therapeutics Inc (ELVN) stock is expected to climb by 2050, reaching an average of $55.64, a $147.61% jump from its current level. However, a wide range of estimates exists, with high and low targets of $58.08 and $57.73, respectively, highlighting the market's uncertainty.
Enliven Therapeutics Inc Stock (ELVN) Year by Year Forecast
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2025
Enliven Therapeutics Inc Stock (ELVN) is expected to reach an average price of $14.36 in 2025, with a high prediction of $22.57 and a low estimate of $6.1509. This indicates an -36.10% fall from the last recorded price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $10.21 | $6.1509 | $11.77 | -54.55% |
| April, 2025 | $12.13 | $7.5378 | $13.75 | -46.01% |
| May, 2025 | $13.01 | $10.41 | $14.48 | -42.12% |
| June, 2025 | $8.4916 | $7.4217 | $14.56 | -62.21% |
| July, 2025 | $13.86 | $8.203 | $22.57 | -38.32% |
| August, 2025 | $13.95 | $12.75 | $15.39 | -37.92% |
| September, 2025 | $9.8211 | $9.5511 | $15.97 | -56.29% |
| October, 2025 | $12.09 | $9.8638 | $13.33 | -46.17% |
| November, 2025 | $13.64 | $9.1004 | $15.83 | -39.31% |
| December, 2025 | $10.19 | $9.187 | $15.53 | -54.65% |
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2026
The predicted value for Enliven Therapeutics Inc (ELVN) in 2026 is set at an average of $10.82. Estimates vary from a peak of $19.13 to a trough of $2.5017, indicating an -51.86% surge from the present price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $10.33 | $9.4059 | $12.02 | -54.02% |
| February, 2026 | $7.9119 | $7.3864 | $10.67 | -64.79% |
| March, 2026 | $5.553 | $4.763 | $9.5174 | -75.29% |
| April, 2026 | $3.4868 | $3.4068 | $7.9657 | -84.48% |
| May, 2026 | $2.9879 | $2.5729 | $5.8224 | -86.70% |
| June, 2026 | $4.6689 | $2.7056 | $5.2139 | -79.22% |
| July, 2026 | $5.0928 | $2.5017 | $8.37 | -77.34% |
| August, 2026 | $8.2938 | $3.9455 | $10.18 | -63.09% |
| September, 2026 | $9.6677 | $6.8616 | $11.04 | -56.98% |
| October, 2026 | $10.68 | $3.9433 | $12.57 | -52.48% |
| November, 2026 | $10.36 | $9.117 | $19.13 | -53.90% |
| December, 2026 | $9.5183 | $8.66 | $11.99 | -57.64% |
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Enliven Therapeutics Inc (ELVN) is $5.9531, with a high forecast of $11.82 and a low forecast of $0.0823. This indicates an -73.51% decrease from the last price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $6.7949 | $5.4466 | $11.63 | -69.76% |
| February, 2027 | $7.5115 | $5.989 | $10.22 | -66.57% |
| March, 2027 | $9.1422 | $5.0756 | $11.82 | -59.31% |
| April, 2027 | $7.4288 | $5.2305 | $8.9005 | -66.94% |
| May, 2027 | $5.8754 | $5.5063 | $8.1051 | -73.85% |
| June, 2027 | $5.1362 | $3.3112 | $5.9587 | -77.14% |
| July, 2027 | $1.7628 | $0.9545 | $5.6888 | -92.16% |
| August, 2027 | $1.1694 | $0.3306 | $2.5419 | -94.80% |
| September, 2027 | $0.2101 | $0.0823 | $2.105 | -99.06% |
| October, 2027 | $3.9367 | $0.1043 | $4.4967 | -82.48% |
| November, 2027 | $3.5333 | $0.3533 | $4.755 | -84.28% |
| December, 2027 | $6.184 | $3.1475 | $7.274 | -72.48% |
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2028
In 2028, Enliven Therapeutics Inc (ELVN) is projected to reach an average price of $7.9054, with a high projection of $15.70 and a low estimate of $0.1094. This indicates an -64.82% fall from the last price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $4.4006 | $4.0006 | $7.5323 | -80.42% |
| February, 2028 | $9.0672 | $0.4649 | $9.3272 | -59.65% |
| March, 2028 | $10.70 | $5.6955 | $15.70 | -52.39% |
| April, 2028 | $4.9866 | $4.51 | $7.7111 | -77.81% |
| May, 2028 | $3.1643 | $1.3421 | $5.6121 | -85.92% |
| June, 2028 | $5.4964 | $1.0509 | $6.1853 | -75.54% |
| July, 2028 | $4.5385 | $2.6885 | $7.8219 | -79.80% |
| August, 2028 | $3.2962 | $1.274 | $4.944 | -85.33% |
| September, 2028 | $1.2583 | $0.3672 | $3.6717 | -94.40% |
| October, 2028 | $0.8204 | $0.1094 | $1.8689 | -96.35% |
| November, 2028 | $2.4019 | $2.098 | $1.7019 | -89.31% |
| December, 2028 | $3.4898 | $3.3653 | $2.2208 | -84.47% |
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2029
The 2029 price forecast for Enliven Therapeutics Inc Stock (ELVN) is $6.2502 on average, with a high prediction of $12.27 and a low estimate of $0.2318. This represents an -72.18% decrease from the previous price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $2.6521 | $3.5677 | $2.7677 | -88.20% |
| February, 2029 | $1.24 | $0.9026 | $1.8966 | -94.48% |
| March, 2029 | $1.4221 | $0.4334 | $3.0421 | -93.67% |
| April, 2029 | $2.4343 | $0.2318 | $3.9042 | -89.17% |
| May, 2029 | $4.6119 | $0.5109 | $5.6319 | -79.48% |
| June, 2029 | $3.5941 | $2.2741 | $12.27 | -84.01% |
| July, 2029 | $1.50 | $0.36 | $5.2056 | -93.32% |
| August, 2029 | $0.5654 | $0.5969 | $3.5838 | -97.48% |
| September, 2029 | $0.0478 | $1.0778 | $0.6622 | -99.79% |
| October, 2029 | $0.6168 | $1.0632 | $3.8199 | -97.25% |
| November, 2029 | $1.6455 | $0.4937 | $3.5887 | -92.68% |
| December, 2029 | $1.3679 | $1.5548 | $0.3117 | -93.91% |
Enliven Therapeutics Inc Stock (ELVN) Price Forecast for 2030
Enliven Therapeutics Inc Stock (ELVN) is expected to reach an average price of $4.4672 in 2030, with a high forecast of $8.8356 and a low forecast of $0.0987. This signifies an -80.12% decrease from the last price of $22.47.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.8233 | $2.261 | $2.6933 | -87.44% |
| February, 2030 | $5.3256 | $3.4595 | $3.4256 | -76.30% |
| March, 2030 | $7.768 | $5.8837 | $5.648 | -65.43% |
| April, 2030 | $8.1303 | $7.0941 | $6.3453 | -63.82% |
| May, 2030 | $6.3457 | $7.2396 | $6.4396 | -71.76% |
| June, 2030 | $5.7181 | $4.529 | $4.0281 | -74.55% |
| July, 2030 | $1.7835 | $2.6223 | $3.0512 | -92.06% |
| August, 2030 | $0.8358 | $1.5458 | $0.5072 | -96.28% |
| September, 2030 | $0.3118 | $0.4682 | $2.702 | -98.61% |
| October, 2030 | $0.3964 | $0.0987 | $8.8356 | -98.24% |
| November, 2030 | $2.8634 | $0.7433 | $2.165 | -87.26% |
| December, 2030 | $5.4502 | $3.2451 | $4.1602 | -75.74% |
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):